v3.0.7
Please consider this website is continuously evolving and still under development
to harmonize automatic data extraction and integrate manual data annotation.
Column | Value |
---|---|
Trial registration number | NCT04366050 |
Full text link
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
|
First author
Last imported at : Jan. 29, 2021, 12:31 a.m. Source : ClinicalTrials.gov |
|
Contact
Last imported at : Jan. 29, 2021, 12:31 a.m. Source : ClinicalTrials.gov |
llazaro@health.ucsd.edu |
Registration date
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
2020-04-28 |
Recruitment status
Last imported at : Jan. 4, 2023, 4 p.m. Source : ClinicalTrials.gov |
Unknown |
Study design
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
RCT |
Allocation
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
Randomized |
Design
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
Parallel |
Masking
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
Blind label |
Center
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
single-center |
Study aim
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
Treatment |
Inclusion criteria
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
inclusion criteria: - age ≥ 18 years - willing and able to provide written informed consent prior to performing study procedures - severe acute respiratory syndrome coronavirus (sars-cov)-2 infection confirmed by polymerase chain reaction (pcr) test ≤ 5 days before randomization or clinical presentation consistent with covid-19 infection (fever or cough or shortness of breath) with positive igm serology - currently hospitalized or in an emergency department - peripheral capillary oxygen saturation (spo2) ≥ 93% on room air at screening |
Exclusion criteria
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
- participation in any other clinical trial of an experimental treatment for covid-19 (use of hydroxycholoroquine or compassionate use of choloroquine or azithromycin is allowed) - concurrent treatment with other agents with actual or possible direct acting antiviral activity against sars-cov-2 is prohibited < 24 hours prior to study drug/placebo dosing - requiring mechanical ventilation at screening - requiring icu care at admission - nsaid use within 12 hours of randomization or requiring continued nsaid use during this trial - alanine aminotransferase (alt) or aspartate aminotransferase (ast) > 5 x upper limit of normal (uln) - estimated gfr < 40 ml/min - history of serum creatinine ≥ 2 mg/dl in the previous 28 days - systolic bp < 100 mm hg or diastolic bp < 65 mm hg - hypersensitivity to acei - history of angioedema - outpatient use of ace inhibitor or angiotensin ii receptor blocker in the last 7 days - history of renal artery stenosis - serum potassium ≥ 5.1 meq/l - pregnancy or breastfeeding - use of aliskiren, amifostine, lithium, sacubitril within 7 days |
Number of arms
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
2 |
Funding
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
University of California, San Diego |
Inclusion age min
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
18 |
Inclusion age max
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
None |
Countries
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
United States |
Type of patients
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
Moderate disease at enrollment |
Severity scale
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
3: Moderate disease at enrollment |
Total sample size
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
560 |
primary outcome
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
Composite of mortality or need for ICU admission or ventilator use |
Notes
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
None |
Phase
Last imported at : Feb. 25, 2021, 7:58 p.m. Source : ClinicalTrials.gov |
Phase 2 |
Arms
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
[{"arm_notes": "", "treatment_id": 1061, "treatment_name": "Ramipril", "treatment_type": "Cardiovascular agents", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}] |